The public prices below are patient-access benchmarks, not wholesale quotes. Product strengths are shown to identify commercial terms, not to recommend treatment or imply clinical interchangeability.
What do the manufacturer self-pay offers actually say?
Snapshot: November 17, 2026. Eligibility, taxes, fees and modification rights must be checked against the applicable terms before quoting a patient.
| Product and presentation | Published patient medicine price | Unit and important conditions | Primary source |
|---|---|---|---|
| Wegovy pill | $149 at 1.5 mg; $199 at 4 mg; $299 at 9 mg or 25 mg | One bottle of 30 tablets. | NovoCare offer page, checked November 17, 2026 |
| Wegovy injection | New eligible patients: $199 for each of two introductory fills at 0.25 mg and 0.5 mg. Standard self-pay: $349; HD 7.2 mg: $399 | Four pens per offer-defined month. Introductory offer through December 31, 2026. | NovoCare offer page, checked November 17, 2026 |
| Zepbound single-dose vials or KwikPen | $299 at 2.5 mg; $399 at 5 mg; $449 at 7.5–15 mg under the Journey offer | 28 days. Continued higher-dose discount requires purchase within 45 days of the preceding delivery/receipt. Regular prices: $499 at 7.5 mg; $699 at 10–15 mg. | Lilly HCP terms, checked November 17, 2026 |
| Foundayo tablets | Current offers: $149 at 0.8 or 2.5 mg; $199 at 5.5 mg; $299 at 9, 14.5 or 17.2 mg | 30 days. Temporary 2.5/5.5 mg reductions end December 31, 2026; regular prices are $199/$299. Highest strengths require the 45-day refill condition for $299; otherwise $349. | Lilly full terms, checked November 17, 2026 |
The terms demonstrate why an introductory or conditional price is not a dependable steady-state budget. In particular, refill administration is a commercial variable: missing the specified window can change the medicine charge even without a change in prescribed strength. Zepbound terms; Foundayo terms (zepbound.lilly.com)
Can telehealth subscriptions be cheaper than standard self-pay?
Yes, published subscription offers introduce a different comparison—but the commitment and service terms must be priced too. Novo Nordisk’s March 31, 2026 announcement set out the following medicine prices through participating telehealth providers:
| Subscription duration | Wegovy pen, listed standard strengths | Wegovy pill, 9 mg or 25 mg |
|---|---|---|
| Three months | $329/month | $289/month |
| Six months | $299/month | $269/month |
| Twelve months | $249/month | $249/month |
Source and status: manufacturer-announced prices on March 31, 2026, announcement checked November 17; not an executable quote from a particular platform. Novo states that complete terms vary by provider and that limited-time offers are separate from subscriptions. Novo subscription announcement (novonordisk-us.com)
Before treating a subscription as a saving, obtain written answers on:
- Whether care or membership charges are additional.
- Whether “month” means a billing month, 28 days or 30 days of medicine.
- Payment timing and whether unused future periods are refundable.
- What happens after clinical discontinuation, a prescription change or loss of eligibility.
- Whether the price is available to an independent clinic’s patients without moving their clinical relationship.
These questions are procurement recommendations, not assumptions about every participating platform.
How should Medicare GLP-1 Bridge pricing be treated?
As a separate coverage route—not as a general cash-price benchmark. CMS states that the demonstration runs from July 1, 2026 through December 31, 2027, outside the normal Part D benefit payment flow. Its materials specify a $245 net price per monthly supply and a $50 beneficiary copayment, subject to eligibility. CMS program page; CMS expectations and FAQs
The $50 is not the total medicine cost, and $245 is not a clinic purchasing price. CMS also distinguishes Bridge access from prescriptions eligible for ordinary Part D coverage; the routes cannot be assumed interchangeable. CMS FAQs
What is known about semaglutide wholesale price versus patient cash price?
A future published WAC is known; a general clinic acquisition price is not. Novo’s February 24 announcement provides the January 1, 2027 effective date and $675 monthly WAC, while expressly saying the change does not affect direct-to-patient self-pay prices. It should not be applied retroactively to November 2026 purchasing. Novo list-price announcement (novonordisk-us.com)
This research did not obtain matched, executable wholesaler quotations for the target provider cohort. Consequently, it does not publish an invented clinic discount percentage, acquisition-price range, dispensing fee or shipping-fee benchmark.
For a GLP-1 pharmacy dispensing and shipping fees comparison, request separate lines for medicine, dispensing, delivery, supplies, implementation, platform charges, exceptional handling and minimum commitments. Identify the payer for each line.
Explore the table row by row
A working view of the research
Wegovy pill
- Published patient medicine price
- $149 at 1.5 mg; $199 at 4 mg; $299 at 9 mg or 25 mg
- Unit and important conditions
- One bottle of 30 tablets.
- Primary source
- NovoCare offer page, checked November 17, 2026
Sources cited on this page
- novocare.com · Source 1 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- zepbound.lilly.com · Source 2 ↗https://zepbound.lilly.com/hcp/coverage-savings
- lilly.com · Source 3 ↗https://www.lilly.com/lillydirect/foundayo/foundayo-full-terms-conditions
- novonordisk-us.com · Source 4 ↗https://www.novonordisk-us.com/media/press-releases/wegovy-subscription-program-telehealth-savings.html
- cms.gov · Source 5 ↗https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- cms.gov · Source 6 ↗https://www.cms.gov/files/document/medicare-glp-1-bridge-expectations-faqs.pdf
- novonordisk-us.com · Source 7 ↗https://www.novonordisk-us.com/media/press-releases/novo-nordisk-lowers-wegovy-ozempic-list-price.html